GARDP and the University of Queensland have announced an expansion of their partnership to tackle the growing global threat of serious bacterial infections.
GARDP has today announced an agreement with Swiss biopharmaceutical company BioVersys to explore opportunities to accelerate the research and development of antibiotics for serious bacterial infections.
GARDP and Venatorx Pharmaceuticals today announced a collaboration to accelerate the development of cefepime-taniborbactam, an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA).
GARDP has today announced an agreement with Daiichi Sankyo for GARDP to access and screen the Daiichi Sankyo chemical library. The library will be tested by Institut Pasteur Korea with the goal of discovering novel antibacterial compounds.
The Global Antibiotic Research and Development Partnership (GARDP) is pleased to announce that Dr Mercedes Tatay has joined the Board. As a specialist in infectious diseases with a remarkable track record working with Médecins Sans Frontières (MSF) on humanitarian medical responses and public health interventions, Dr Tatay brings exceptional experience in ensuring treatments are developed […]
BERLIN – The Global Antibiotic Research and Development Partnership (GARDP) is pleased to announce continued support from the Dutch Ministry of Health, Welfare and Sport. The funding of €5 million will be used to support GARDP’s efforts to develop new treatments for drug-resistant infections and to ensure sustainable access, promoting responsible use and affordability to […]